Thirty-four patients were tested for Janus kinase 2 (JAK2) V617F mutation, among which 23 were positive including 22 patients also being diagnosed with MPN according to the WHO diagnostic criteria. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.